Stocks of the Hour: PainChek, Chimeric Therapeutics, Torque Metals
A snapshot of the stocks on the move, featuring PainChek (ASX:PCK), Chimeric Therapeutics (ASX:CHM) and Torque Metals (ASX:TOR).
Read MoreTag: CHM
Chimeric Therapeutics (ASX:CHM) – Webinar Presentation
Jennifer Chow – CEO & Managing Director – Chimeric Therapeutics (ASX:CHM) is a clinical-stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.
Read MoreStocks of the Hour: QX Resources, Chimeric Therapeutics, Alliance Nickel
A snapshot of the stocks on the move, featuring QX Resources (ASX:QXR), Chimeric Therapeutics (ASX:CHM) and Alliance Nickel (ASX:AXN).
Read MoreChimeric Therapeutics shows promise in ovarian and pancreatic cancers
Chimeric Therapeutics (ASX:CHM), an Australian company specialising in cell therapy, has reported significant in vitro findings for its chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy, CHM 1301. These preclinical results highlight the therapy's notable efficacy against ovarian and pancreatic cancers, suggesting potential advancements in cancer treatment.
Read MoreStocks of the Hour: Chimeric Therapeutics, Armada, Site Group International, Linius Technologies
A snapshot of the stocks on the move, featuring Chimeric Therapeutics (ASX:CHM), Armada (ASX:AMM), Site Group International (ASX:SIT) and Linius Technologies (ASX:LNU).
Read MoreStocks of the Hour: Origin Energy, Sunstone Metals, Chimeric Therapeutics
A snapshot of the stocks on the move, featuring Origin Energy (ASX:ORG), Sunstone Metals (ASX:STM) and Chimeric Therapeutics (ASX:CHM).
Read MoreStocks of the Hour: Chimeric Therapeutics, Power Minerals, James Bay Minerals
A snapshot of the stocks on the move, featuring Chimeric Therapeutics (ASX:CHM), Power Minerals (ASX:PNN) and James Bay Minerals (ASX:JBY).
Read MoreChimeric Therapeutics (ASX:CHM) – Webinar Presentation
Jennifer Chow – CEO – Chimeric Therapeutics (ASX:CHM) is a clinical-stage therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.
Read MoreStocks of the Hour: QX Resources, Chimeric Therapeutics, Peako, IVE Group
A snapshot of the stocks on the move, featuring QX Resources (ASX:QXR), Chimeric Therapeutics (ASX:CHM), Peako (ASX:PKO) and IVE Group (ASX:IGL).
Read MoreExtending the lives of patients with brain cancer
Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses efficacy results for the company's glioblastoma therapy.
Read MoreStocks of the Hour: Immutep, Chimeric Therapeutics, Sayona Mining
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM; NASDAQ:IMMP), Chimeric Therapeutics (ASX:CHM) and Sayona Mining (ASX:SYA; OTCQB:SYAXF).
Read MoreStocks of the Hour: Way2VAT, Liontown Resources, Chimeric Therapeutics
A snapshot of the stocks on the move, featuring Way2VAT (ASX:W2V), Liontown Resources (ASX:LTR) and Chimeric Therapeutics (ASX:CHM).
Read MoreStocks of the Hour: Chimeric Therapeutics, Apollo Minerals, Caspin Resources
A snapshot of the stocks on the move, featuring Chimeric Therapeutics (ASX:CHM), Apollo Minerals (ASX:AON) and Caspin Resources (ASX:CPN).
Read MoreStocks of the Hour: Chimeric Therapeutics, Apollo Minerals, Morella Corporation
A snapshot of the stocks on the move, featuring Chimeric Therapeutics (ASX:CHM), Apollo Minerals (ASX:AON) and Morella Corporation (ASX:1MC).
Read MoreASX closes 0.4% higher as gold price hits five-month low
The price of gold has dropped to a five-month low due to improved expectations of a gentle economic slowdown in the US and a series of disappointing economic indicators from China.
Read MoreStocks of the Hour: Lake Resources, Chimeric Therapeutics, Sunstone Metals
A snapshot of the stocks on the move, featuring Lake Resources (ASX:LKE), Chimeric Therapeutics (ASX:CHM) and Sunstone Metals (ASX:STM).
Read MoreChimeric Therapeutics (ASX:CHM) – Webinar Presentation
07 Jul 2023 – The mission of Chimeric Therapeutics (ASX:CHM) is to bring that promise to life for more patients with cancer by discovering, developing and commercialising cell therapies with the most curative potential.
Read MoreChimeric Therapeutics (ASX:CHM) launches phase 1b glioblastoma trial
27 Jun 2023 – Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company's lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial.
Read MoreChimeric Therapeutics’ Portfolio of Cancer Therapies
Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on the clinical-stage cell therapy company’s recent therapy trials.
Read MoreChimeric Therapeutics (ASX: CHM) enters research agreement to advance cell therapy portfolio
Chimeric Therapeutics CEO and Managing Director Jennifer Chow discusses the company’s new agreement with Case Western Reserve University.
Read MoreChimeric Therapeutics (ASX:CHM) Expands Cancer Trials
Chimeric Therapeutics CEO / MD Jennifer Chow provides an update on clinical trial progression and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.
Read More
